GlassScriptPhysician profile
Mark Anderson Schmidt
NPI 1023000684
$83,702.33
in general payments reported to CMS, 2019-2025
15 companies · $35.06 in 2025
The $35.06 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $24K · 2021: $23K · 2022: $5,997 · 2023: $261 · 2024: $145 · 2025: $35.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.99 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roanoke Area Surgical Lasers, LLC | $81,250.00 | 2019-2022 | |
| Coloplast Corp | $797.19 | 2020-2024 | Speedicath, Titan |
| Astellas Pharma US INC | $714.38 | 2019-2022 | |
| Pfizer INC. | $511.86 | 2019-2023 | |
| Myovant Sciences INC. | $117.51 | 2021-2022 | |
| Janssen Biotech, INC. | $68.44 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $46.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $31.64 | 2020 | |
| Allergan, INC. | $31.60 | 2019 | |
| Blue Earth Diagnostics | $25.84 | 2022 | |
| Urogen Pharma, INC. | $23.65 | 2022 | |
| Amgen INC. | $22.37 | 2019 | |
| Abbvie INC. | $14.07 | 2019 | |
| Boston Scientific Corporation | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$188,710.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.